US drug manufacturer Eli Lilly has completed its acquisition of radiopharmaceutical company Point Biopharma for approximately $1.4 billion.

Eli Lilly announced that it is acquiring radiopharmaceutical company Point Biopharma for $12.50 per share in cash, valuing the deal at approximately $1.4 billion. Point...